St. Louis, MO
Home ► Blog ► FDA & Prescription Drugs ► Invokana
The SGLT2 inhibitor Invokana has come under fire recently because of the increased risk of lower limb amputations caused by one of its key ingredients, canagliflozin. Physicians in California are hurrying to switch patients from Invokana to other dia Read More »
Last month at the American Diabetes Association’s (ADA) 77th Scientific Sessions, AstraZeneca Plc. presented new data supporting the safety and effectiveness of their SLGT-2 inhibitor Farxiga. This data is in direct contention with the FDA̵ Read More »
Invokana Black Box Warning Pharmaceutical manufacturer Johnson & Johnson’s Invokana (“the SGLT-2 canagliflozin pharmaceutical marketed to treat type 2 diabetes and off-label for type 1 diabetes”), along with related drugs Invoka Read More »
A summary of the most active product liability cases in 2016.
Read More »
Contact us by phone at 1-888-508-6752 or email us below.
© 2017 TorHoerman Law LLC.
The contents of this webpage have been prepared by TorHoerman Law, LLC for informational purposes only. None of this information is intended as either legal or medical advice or opinions. No attorney/client relationship is established with use of this website. Sending or receiving information through this site, posting to our blogs/news site does not establish an attorney/client relationship. An attorney/client relationship with TorHoerman Law is established only by an express and written agreement by TorHoerman Law to represent you. Our attorneys make a case-by-case assessment of any claims and results may vary depending on the facts concerning any case. The attorneys at TorHoerman Law are licensed to practice in Illinois, Missouri, and California. In some circumstances, cases may be sent to other qualified lawyers. In those circumstances, TorHoerman Law maintains joint responsibility.
Wesite Design & Development by Kaizen Coding